Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Natalia, Rydz"'
Autor:
Ilja Oomen, Amal Abdi, Ricardo M. Camelo, Fábia M.R.A. Callado, Luany E.M. Carvalho, Ilenia L. Calcaterra, Manuel Carcao, Giancarlo Castaman, Jeroen C.J. Eikenboom, Kathelijn Fischer, Vivian K.B. Franco, Martijn W. Heymans, Frank W.G. Leebeek, David Lillicrap, Cláudia S. Lorenzato, Maria Elisa Mancuso, Davide Matino, Matteo N.D. Di Minno, Alex B. Mohseny, Johannes Oldenburg, Suely Meireles Rezende, Georges-Etienne Rivard, Natalia Rydz, Saskia E.M. Schols, Jan Voorberg, Karin Fijnvandraat, Samantha C. Gouw
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 8, Iss 7, Pp 102580- (2024)
Background: Inhibitor eradication to restore factor (F)VIII efficacy is the treatment goal for persons with severe hemophilia A (HA) and inhibitors. Immune tolerance induction (ITI) is demanding and successful in about 70% of people. Until now, it ha
Externí odkaz:
https://doaj.org/article/81986c3b0b0948108260f0f7bf03d9f4
Publikováno v:
Advances in Hematology, Vol 2024 (2024)
Sickle cell disease (SCD) is a common genetic disorder with potentially serious sequelae that can be effectively treated with hydroxyurea. Despite its favorable benefit-risk profile, hydroxyurea uptake in patients with SCD is low. A pilot study was c
Externí odkaz:
https://doaj.org/article/1671a776a7144da19b925baa4a2d71b4
Autor:
Erika Wall, John Podstawka, Jeffery M. Patterson, Lauren Bolster, M. Dawn Goodyear, Natalia Rydz, Haowei L. Sun
Publikováno v:
Thrombosis Research. 225:87-94
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b161d53b50bf58075cb16d0eec6a5239
https://doi.org/10.1016/j.thromres.2023.03.011
https://doi.org/10.1016/j.thromres.2023.03.011
Autor:
John Podstawka, Erika Wall, Lauren Bolster, Jeffery M. Patterson, M. Dawn Goodyear, Natalia Rydz, Haowei L. Sun
Publikováno v:
Thrombosis Research. 220:5-11
The optimal choice of second-line treatment for immune thrombocytopenia (ITP) is unclear. Guidelines recommend either rituximab, splenectomy, or thrombopoietin receptor agonists (TPO-RA). There is, however, scarce data comparing treatment patterns, o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac08741d2201473cc0fe69ee04317571
https://doi.org/10.1016/j.thromres.2022.09.021
https://doi.org/10.1016/j.thromres.2022.09.021
Autor:
Analía Sánchez-Luceros, Adriana I. Woods, Emilse Bermejo, Shilpa Shukla, Suchitra Acharya, Michelle Lavin, Natalia Rydz, Maha Othman
Publikováno v:
Platelets, Vol 28, Iss 5, Pp 484-490 (2017)
Despite the increased worldwide awareness, over the last decade, of the platelet-type von Willebrand Disease (PT-VWD), many uncertainties remain around this rare platelet bleeding disorder. This report aims to correctly identify and study the phenoty
Externí odkaz:
https://doaj.org/article/2ee8464533f5442cbbdcc252fe76142c
Autor:
John Podstawka, Erika Wall, Lauren Bolster, Jeffery M. Patterson, M. Dawn Goodyear, Natalia Rydz, Haowei Linda Sun
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a0242154004437446eb8db3fcceff16
https://doi.org/10.2139/ssrn.4167531
https://doi.org/10.2139/ssrn.4167531
Publikováno v:
Haemophilia. 27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9313d05555e9a0ce8896af4ef8bccc39
https://doi.org/10.1111/hae.14415
https://doi.org/10.1111/hae.14415
Publikováno v:
BMJ Case Rep
Small cell lung cancer (SCLC) is a deadly and rapidly progressive disease that can present with various paraneoplastic syndromes on initial workup. Acquired factor VIII (FVIII) deficiency, also known as acquired haemophilia A (AHA), has been identifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815d57e4a39af3e1c0ef991cdc8e45ad
https://europepmc.org/articles/PMC7845684/
https://europepmc.org/articles/PMC7845684/
Publikováno v:
Transfusion and Apheresis Science. 57:724-730
Acquired factor XIII (FXIII) deficiency is a rare bleeding disorder that can manifest with spontaneous or delayed life-threatening hemorrhage. Causes of acquired deficiency include immune-mediated inhibition, as well as non-immune FXIII hyperconsumpt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa733918180bd36eda12da693e6aa78e
https://doi.org/10.1016/j.transci.2018.10.013
https://doi.org/10.1016/j.transci.2018.10.013
Publikováno v:
Haemophilia. 24:720-725
INTRODUCTION Desmopressin is an effective haemostatic agent for patients with non-severe haemophilia A; however, response may differ between patients of similar severity. Responsiveness is classified based on various cut-off values for plasma levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fb62c9018db60765ef7409c7a310d5c
https://doi.org/10.1111/hae.13586
https://doi.org/10.1111/hae.13586